News

The safety and efficacy of Xanamem is currently being studied in clinical trials. Xanamem is not approved for use by the US Food & Drug Administration or any other regulatory authority.

22 Jul 2025	PR Newswire	A novel oral treatment for Alzheimer’s: Actinogen’s pivotal trial currently recruiting participants in the US
01 Jul 2025	FIVEAA	FIVEAA Adelaide radio interview with Dr Steven Gourlay on once-a-day Alzheimer’s pill [8m 25s]
01 Jul 2025	Hobart Mercury	Pill could halt Alzheimer’s – Potential ‘holy grail’ drug gets 100th patient for trial
01 Jul 2025	Herald Sun	Once-a-day pill milestone – Trials on Alzheimer’s wonder drug show ‘definite improvement’ in patients
30 Jun 2025	Nine News Melbourne	Alzheimer’s trial – Melbourne hospitals play key role
30 Jun 2025	PR Newswire	Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline
04 Jun 2025	Courier Mail	Alzheimer’s wonder drug shows promise
15 May 2025	Webcast Video Recording	ACW Clinical Trials Science Forum 2025 – The critical importance of preparing for commercialization [1.00 hr]
02 Apr 2025	Daily Telegraph	Dementia disaster warning
26 Mar 2025	The Australian	Top of mind: ASX companies tackling neurological disorders
05 Mar 2025	HotCopper	Executive Interview HotCopper with Dr Steven Gourlay: Xanamem: Alzheimer’s breakthrough set for 2025, 2026
27 Feb 2025	The Australian	The furore over how to treat Alzheimer’s just got a lot more complicated
12 Feb 2025	PR Newswire	Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal
05 Feb 2025	PR Newswire	Actinogen announces new and unique nonproprietary name of ’emestedastat’ for Xanamem
05 Feb 2025	ABC Radio	Audio Recording: ABC Radio Melbourne interview with Dr Steven Gourlay (3m 28s)
05 Feb 2025	Hobart Mercury	Drug Win for Aussie firm
05 Feb 2025	10 First News	Executive Interview: 10 First News with Dr Steven Gourlay
24 Jan 2025	Actinogen	Executive Interview: Edison Group interviews Dr Steven Gourlay (23m39s)
12 Jan 2025	Actinogen	Video recording: Actinogen Medical at the Sachs Neuroscience Innovation Forum 2025 (17m: 44s)
06 Jan 2025	Daily Mail Online	Hopes new drug likened to ‘exercise in a pill’ will deal a major blow against Alzheimer’s
09 Dec 2024	PR Newswire	Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer’s disease trial
16 Nov 2024	7 News Australia	New magic pill to help treat Alzheimer’s disease
16 Nov 2024	Sky News Australia	New breakthrough pill being trialled to combat Alzheimer’s
16 Nov 2024	10 News Australia	Xanamem: The potential ‘Holy Grail’ for the treatment of Alzheimers
16 Nov 2024	Courier Mail	Alzheimer’s Hope: Disease breakthrough could be ‘Holy Grail’
16 Nov 2024	Daily Telegraph	New pill promises hope for millions: ‘Holy Grail’ for Alzheimer’s
16 Nov 2024	Herald Sun	Pill may deliver hope for millions: ‘Holy Grail’ for Alzheimer’s
18 Sep 2024	Actinogen	Webcast Video Recording: ACW $11.1 capital raising
30 Aug 2024	Actinogen	Webcast Video Recording: Actinogen updated Depression Trial results and implications presentation
26 Aug 2024	PR Newswire	Actinogen announces further positive results on depression in the XanCIDD phase 2a trial
12 Aug 2024	Actinogen	Webcast Video Recording: Actinogen XanaCIDD topline results presentation
12 Aug 2024	PR Newswire	Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial
26 Jun 2024	PR Newswire	Positive Xanamem® biomarker trial published in the Journal of Alzheimer’s Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau
03 Jun 2024	Actinogen	Video Recording: ACW Australian Dementia Research Forum poster presentation
24 May 2024	Actinogen	Webcast Video Recording: Actinogen Clinical Trials Science Forum 2024 – Pipeline in a Pill
06 May 2024	Actinogen	Video interview: [2:49 mins] Market Link interview with ACW CEO, Steven Gourlay
03 May 2024	Corporate Presentations	Video Presentation: Actinogen May 2024 $8.9m capital raising webinar
22 Apr 2024	PR Newswire	Enrolment completed in Actinogen’s XanaCIDD phase 2a cognition & depression trial
15 Apr 2024	PR Newswire	First patient treated in Actinogen’s XanaMIA phase 2b Alzheimer’s disease trial
24 Jan 2024	PR Newswire	Positive Xanamem® human PET study published in the Journal of Alzheimer’s Disease demonstrating robust CNS target enzyme occupancy
08 Jan 2024	Corporate Presentations	Company Presentation: ACW CEO & CMO present at Sachs Neuroscience Innovation Forum & JPM week meetings
07 Jan 2024	Corporate Presentations	Video Presentation: ACW CMO presents at Sachs Neuroscience Innovation Forum
28 Nov 2023	PR Newswire	Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024
15 Nov 2023	Corporate Presentations	Company Presentation: ACW CEO presents at Bell Potter Healthcare Conference 2023
25 Oct 2023	Corporate Presentations	Company Presentation: ACW CMO presents academic poster at CTAD 2023 conference
18 Oct 2023	Corporate Presentations	Company Presentation: ACW CEO presentation for meetings at BIO Investor Forum USA
13 Oct 2023	PR Newswire	Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Boston
06 Oct 2023	Actinogen	Company Presentation: ACW CEO presents to Dementia Trials Australia conference
29 Sep 2023	Actinogen	Company Presentation: ACW Clinical Scientist presents to the Asian Society Against Dementia congress
26 Sep 2023	PR Newswire	Actinogen optimizes XanaMIA Phase 2b Alzheimer’s disease trial design and provides general business update